What Is the Risk of ET Progressing to Myelofibrosis or AML?

For most people living with essential thrombocythemia (ET), the disease remains stable for many years and never progresses to a more severe condition. The fear of ET transforming into a different disease is completely normal, but the actual statistical risk is quite low. Research shows that over a 15-year period, the chance of ET progressing to post-ET myelofibrosis (post-ET MF)—a chronic myeloid neoplasm characterized by scar tissue building up in the bone marrow and altering blood production—is approximately 9% on average ^[1]. The risk of ET transforming into acute myeloid leukemia (AML)—an acute cancer of immature myeloid blood-forming cells—is even lower, at an average of around 2% over 15 years ^[1]. While it is important to monitor for signs of change, the vast majority of patients will manage ET as a chronic condition without it ever transforming.

The Statistics: What Does the Data Say?

Understanding the numbers can help put the risk into perspective, but it is important to know that these are historical group averages, not a prediction of your personal future. Estimates vary widely depending on the study’s diagnostic criteria, follow-up length, and patient ages.

• Risk of Myelofibrosis: Based on reviews of historical studies, about 0.8% to 4.9% of ET patients develop post-ET MF within 10 years of diagnosis ^[2]. By 15 years, this risk range rises to between 4% and 11% ^[2].
• Risk of Acute Myeloid Leukemia (AML): Transformation to AML is rare. At 10 years, the estimated risk is approximately 0.7% to 3.0% ^[2]. By 15 years, studies report a range of 2.1% to 5.3% ^[2].

Age and competing health risks play a significant role. For instance, a recent nationwide registry study estimated a 10-year AML risk of 4.7% for a patient diagnosed with ET at age 70, highlighting that risk increases with older age and longer disease duration ^[3].

How Your Care Team Monitors for Progression

Progression does not always cause noticeable symptoms right away. In many cases, early signs of change are detected through routine monitoring ^[4]. This is why keeping your scheduled appointments is crucial.

During routine follow-ups, your care team will track:

• Complete Blood Count (CBC) Trends: A steady, unexplained drop in hemoglobin (anemia) or changes in white blood cell counts (leukocytosis) can be early indicators that the bone marrow environment is shifting ^[2][4].
• Physical Examinations: Your doctor will feel your abdomen to check if your spleen is enlarging (splenomegaly) ^[5].
• Symptom Review: Discussing any new fatigue, night sweats, or bleeding issues.

Tests like bone marrow biopsies or advanced genetic sequencing panels are not typically performed on a rigid schedule for stable ET. Instead, they are used when blood counts or physical symptoms suggest that a reassessment is clinically necessary ^[6][7].

What Factors Are Associated with Progression?

While anyone with ET has a small risk of their disease changing, researchers have identified certain factors associated with a higher likelihood of progression. However, having these risk markers does not mean transformation is inevitable.

Factors Linked to Myelofibrosis

• Genetic Profiles: Having a high allele burden (the percentage of mutated DNA molecules in a tested sample) of the JAK2 mutation, or having specific CALR or MPL mutations, is associated with a higher risk of scarring in the marrow ^[8][9].
• Additional Mutations: Finding other mutations beyond the primary driver (such as ASXL1, SF3B1, or IDH1/2) is linked to an increased likelihood of fibrotic changes ^[10][2]. These findings must be interpreted alongside your overall clinical picture.
• Clinical Signs: Being older, being male, having an enlarged spleen at diagnosis, or having unexplained anemia or leukocytosis are recognized risk factors for post-ET MF ^[2][4].

Factors Linked to AML

• Advanced Age and Duration: The risk of AML naturally increases as patients get older, and a longer duration of having ET also increases the risk ^[3][2].
• High-Risk Mutations: The presence of specific genetic mutations, such as TP53, RUNX1, or ASXL1, is associated with a higher risk of leukemic transformation, though this is still an uncommon event ^[9][11].
• Blood Count Changes: Developing new, unexplained anemia, highly elevated white blood cells, or having abnormal chromosomes (cytogenetics) can be warning signs ^[2].

Changes to Report to Your Doctor

Because symptoms can be caused by many different things—including infections, unrelated illnesses, or your current medications—experiencing a new symptom does not prove your ET is progressing. However, you should contact your hematology office if you develop:

• New or Worsening Severe Fatigue: A profound exhaustion that does not improve with rest, which may indicate a drop in red blood cells ^[5][12].
• Constitutional Symptoms: This includes drenching night sweats (waking up with soaked clothes), persistent unexplained fevers, or losing a significant amount of weight without trying ^[13][14].
• Abdominal Fullness or Early Satiety: Feeling full after eating only a small amount, or discomfort in your upper left abdomen. This often indicates an enlarging spleen ^[13][14].

When to Seek Emergency Care

Some symptoms require immediate emergency medical attention rather than waiting for a hematology appointment. Go to the emergency room or call for immediate help if you experience:

• Uncontrolled Bleeding: New or heavy bleeding that will not stop, black or bloody stools, or vomiting blood. In ET, bleeding can happen if platelets drop too low, but it can also happen when platelets are extremely high (due to a condition called acquired von Willebrand syndrome where platelets become dysfunctional) ^[13][15].
• Signs of a Blood Clot or Stroke: Sudden shortness of breath, chest pain, a painful swollen leg, severe sudden headache, or one-sided weakness/difficulty speaking ^[5][15].
• Severe Infection: A high fever or signs of a serious infection, especially if you are on medications that lower your immune response ^[13].